JEMPERLI DIN 02523434
Health Canada record
| Active ingredient(s) | DOSTARLIMAB 50 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | SCHEDULE D; PRESCRIPTION |
| Class | Human |
| ATC | L01FF07 DOSTARLIMAB |
| Original market date | 22-Feb-2022 |
| Current status date | 22-Feb-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
GlaxoSmithKline Inc. — licence 100630, currently licensed, last inspection rating C (2025-09-15).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 27285 | 2021-12-23 | New Drug Submission (NDS) |